Hospital Medicine Unplugged cover art

Hospital Medicine Unplugged

Hospital Medicine Unplugged

By: Roger Musa MD and Eric Bachrach MD
Listen for free

About this listen

Hospital Medicine Unplugged delivers evidence-based updates for hospitalists—no fluff, just the facts. Each 30-minute episode breaks down the latest guidelines, clinical pearls, and practical strategies for inpatient care. From antibiotics to risk stratification, radiology to discharge planning, you’ll get streamlined insights you can apply on the wards today. Perfect for busy physicians who want clarity, accuracy, and relevance in hospital medicine.

Roger Musa MD and Eric Bachrach MD Hygiene & Healthy Living Physical Illness & Disease
Episodes
  • Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient

    Clinical Pathophysiology and Evidence-Based Management of Delirium Tremens in the Hospitalized Patient
    Mar 16 2026
    In this episode of Hospital Medicine Unplugged, we sprint through delirium tremens—the most dangerous stage of alcohol withdrawal—recognize the neurochemical storm, identify high-risk patients, and treat aggressively with benzodiazepines and supportive care to prevent fatal complications. We begin with epidemiology and why DTs matter. Delirium tremens occurs in 3–5% of hospitalized patients with alcohol withdrawal and represents the most severe manifestation of the withdrawal spectrum. The syndrome combines acute delirium—rapidly fluctuating attention and cognition—with severe autonomic hyperactivity. Historically mortality approached 15%, but with modern aggressive treatment it has fallen to about 1–4%. When death occurs, it is usually due to hyperthermia, malignant arrhythmias, withdrawal seizures, or underlying medical illness. Next comes the neurobiology driving withdrawal. Chronic alcohol exposure forces the brain to compensate for alcohol’s depressant effects. Over time: • NMDA glutamate receptors are upregulated • GABA-A inhibitory receptors are downregulated While alcohol is present, its GABA-enhancing and NMDA-suppressing effects maintain balance. When alcohol is abruptly stopped, that balance collapses. The result is unopposed excitatory neurotransmission, increased glutamate signaling, reduced GABA inhibition, and massive central nervous system hyperexcitability. Additional contributors include increased norepinephrine activity, dopaminergic alterations, and calcium-mediated excitotoxicity, producing the agitation, tremor, and seizure risk characteristic of severe withdrawal. Risk stratification is essential because not every patient with withdrawal develops delirium tremens. The strongest predictor is a prior history of DTs, which carries a likelihood ratio of roughly 2.9 for recurrence. Other important risk factors include: • Recent withdrawal seizures, especially multiple seizures • High CIWA-Ar scores (>15) with tachycardia or hypertension • Older age (≥55 years) • Concurrent illness such as infection, trauma, electrolyte abnormalities, or liver disease • Hypokalemia and metabolic derangements Another key concept is the kindling effect. Repeated withdrawal episodes progressively sensitize neuronal circuits, meaning each withdrawal episode tends to become more severe than the last. The timeline of alcohol withdrawal follows a predictable pattern. • 6–12 hours: early withdrawal—tremor, anxiety, tachycardia • 12–24 hours: alcoholic hallucinosis (visual or auditory hallucinations) • 12–48 hours: withdrawal seizures • 72–96 hours: onset of delirium tremens, typically lasting 2–3 days but up to a week Importantly, about one-third of untreated withdrawal seizures progress to delirium tremens, making early treatment critical. Clinically, DTs presents with severe agitation and delirium combined with autonomic instability. Key features include: • Fluctuating confusion and disorientation • Marked agitation and psychomotor hyperactivity • Tachycardia, hypertension, fever, and diaphoresis • Coarse tremor and hyperreflexia • Vivid visual hallucinations, often insects or animals Diagnosis is clinical—delirium occurring in the context of alcohol withdrawal. The CIWA-Ar scale helps quantify withdrawal severity, but it becomes less reliable once patients develop delirium because it depends on patient responses. In ICU settings, clinicians often switch to CAM-ICU, RASS, MINDS, or DDS scales. Laboratory evaluation should focus on complications and reversible triggers. Important tests include: • Electrolytes (magnesium, potassium, phosphate) • Glucose • Liver function tests • Creatine kinase for rhabdomyolysis risk Neuroimaging should be obtained if the presentation is atypical or focal neurologic deficits are present. Management centers on rapid sedation and physiologic stabilization. Benzodiazepines are first-line therapy, acting as GABA-A agonists to counter the hyperexcitable brain. Two dosing strategies dominate: • Symptom-triggered therapy, which reduces medication exposure and treatment duration • Front-loading with high doses for severe withdrawal (CIWA-Ar ≥19) Clinicians should not fear very high benzodiazepine doses. Severe DTs may require hundreds of milligrams of diazepam per day, and case reports describe successful treatment with 260–480 mg/day. Agent selection depends on clinical context: • Diazepam or chlordiazepoxide – preferred long-acting agents for front-loading • Lorazepam – preferred in liver disease, since it lacks active metabolites For benzodiazepine-refractory DTs, ICU-level therapies may be required. Adjunctive options include: • Phenobarbital, which enhances GABA signaling and may reduce mechanical ventilation risk • Propofol, used in intubated patients with refractory agitation • Dexmedetomidine, an α2-agonist that suppresses sympathetic overactivity while allowing arousable sedation ...
    Show More Show Less
    33 mins
  • Evidence-Based Advances in Chronic Spontaneous Urticaria Management in the Hospitalized Patient

    Evidence-Based Advances in Chronic Spontaneous Urticaria Management in the Hospitalized Patient
    Mar 13 2026
    In this episode of Hospital Medicine Unplugged, we sprint through urticaria—recognize the wheal, distinguish acute from chronic disease, uncover autoimmune drivers, and step through a modern treatment ladder that now includes biologics and BTK inhibitors. We start with the definition and epidemiology. Urticaria is characterized by transient pruritic wheals, angioedema, or both, typically resolving within 24 hours without scarring. While about 20% of people experience urticaria at some point in life, chronic spontaneous urticaria (CSU) affects roughly 1% of the population and disproportionately affects women aged 30–50. The key classification hinges on duration. • Acute urticaria: symptoms lasting <6 weeks • Chronic urticaria: symptoms ≥6 weeks Fortunately, progression from acute to chronic disease occurs in fewer than 8% of cases. Risk factors for chronicity include antithyroid antibodies and poor response to antihistamines. Next comes an important shift in our understanding of etiology. Historically, chronic urticaria was labeled “idiopathic” in most cases. We now know that more than half of patients actually have autoimmune disease mechanisms. Two major autoimmune endotypes exist: Type I autoimmune (autoallergic) CSU • IgE autoantibodies against autoantigens such as thyroid peroxidase or IL-24 • Leads to mast-cell activation similar to allergic disease Type IIb autoimmune CSU • IgG autoantibodies against IgE or the FcεRI receptor • Identified in about 8–10% of patients using strict diagnostic criteria These immune mechanisms explain why less than 35% of CSU cases truly lack detectable autoantibodies. Diagnosis is largely clinical but follows the “7C” framework: Confirm diagnosis, identify causes, assess cofactors, evaluate comorbidities, assess consequences, evaluate biomarkers, and monitor disease course. Routine laboratory testing should remain minimal unless clinical clues suggest otherwise. Recommended baseline tests include: • CBC with differential • ESR or CRP • TSH Certain red flags should trigger referral or further evaluation: • Wheals lasting >24 hours • Residual hyperpigmentation after lesions resolve • Angioedema lasting several days without hives • Systemic symptoms such as fever, arthralgia, or abdominal pain To measure disease activity, clinicians rely on validated tools. The Urticaria Activity Score over 7 days (UAS7) is the gold standard. Patients record itch severity and hive count twice daily, producing a score from 0 to 42. Interpretation: • 0: urticaria-free • 1–6: well controlled • 7–15: mild • 16–27: moderate • 28–42: severe The Urticaria Control Test (UCT) is another practical tool. A score ≥12 indicates good control, while <12 suggests poorly controlled disease. Management follows a stepwise escalation strategy. Step 1: Second-generation H1 antihistamines Agents include cetirizine, loratadine, fexofenadine, levocetirizine, and desloratadine, taken daily rather than as needed. About 40% of patients achieve meaningful symptom reduction with standard dosing. Step 2: Dose escalation If symptoms persist, antihistamine doses can be increased up to fourfold. Evidence suggests quadrupling the dose of a single antihistamine is more effective than combining multiple agents. Step 3: Omalizumab For antihistamine-refractory disease, omalizumab 300 mg every 4 weeks is the standard biologic therapy. Clinical trials show complete remission (UAS7 = 0) in about 36% of patients, with substantially higher response rates in real-world practice. Patients with incomplete response may require higher doses or shorter dosing intervals. Step 4: Cyclosporine For patients who fail omalizumab, cyclosporine (3–5 mg/kg/day) can improve symptoms in more than half of cases, although monitoring for renal toxicity and hypertension is essential. Short courses of systemic corticosteroids (20–50 mg/day for <10 days) may help during severe flares but should never be used long-term. The treatment landscape is expanding rapidly. Two newly approved therapies include: Dupilumab An IL-4 receptor α antagonist approved in 2025 for patients ≥12 years with persistent CSU despite antihistamines. Clinical trials showed complete response in about 31% of patients. Remibrutinib A Bruton tyrosine kinase (BTK) inhibitor approved in 2025 that targets mast-cell signaling downstream of FcεRI activation. Trials demonstrated complete response rates up to ~42% with rapid onset within 2 weeks. Another critical diagnostic consideration is urticarial vasculitis, which can mimic CSU but requires a different approach. Key distinguishing features include: • Lesions lasting >24 hours • Pain or burning rather than itching • Residual hyperpigmentation after resolution Systemic symptoms such as fever, arthralgia, or eye inflammation further increase suspicion. Diagnosis is confirmed by skin biopsy showing leukocytoclastic vasculitis. Finally, we talk prognosis. Chronic ...
    Show More Show Less
    30 mins
  • Managing Acute Exacerbations in Fibrotic Interstitial Lung Disease in the Hospitalized Patient

    Managing Acute Exacerbations in Fibrotic Interstitial Lung Disease in the Hospitalized Patient
    Mar 11 2026
    In this episode of Hospital Medicine Unplugged, we sprint through acute exacerbation of interstitial lung disease (AE-ILD)—recognize the sudden decline, rule out infection and cardiac causes, support oxygenation, and navigate a disease with limited treatment options and high mortality. We begin with the diagnostic framework defined by the 2016 International Working Group. Acute exacerbation is characterized by rapid respiratory deterioration within about 1 month, accompanied by new bilateral ground-glass opacities or consolidation on CT superimposed on pre-existing fibrotic lung disease, with no evidence of cardiac failure or fluid overload. Importantly, this definition now applies across fibrosing interstitial lung diseases, not just idiopathic pulmonary fibrosis (IPF). The critical bedside principle: AE-ILD is a diagnosis of exclusion. Infection, pulmonary embolism, pneumothorax, and heart failure must be aggressively ruled out because they can mimic exacerbations and require completely different management. Next, we turn to pathobiology and why these patients deteriorate so rapidly. Acute exacerbations often represent diffuse alveolar damage superimposed on chronic fibrosis, producing a clinical picture similar to ARDS. However, in some non-IPF ILDs, organizing pneumonia patterns are more common—one reason those patients may respond better to immunosuppressive therapy. Treatment remains challenging because no therapy has definitively proven benefit in randomized trials. Corticosteroids remain the most widely used intervention, but evidence is mixed. Recent data suggest a key difference between ILD subtypes. In non-IPF ILD, higher-dose corticosteroids (>1 mg/kg prednisone equivalent) have been associated with improved survival and lower 90-day mortality. Early tapering—reducing doses by more than 10% within the first two weeks—may further improve outcomes. In contrast, IPF exacerbations respond less predictably, and some studies suggest high-dose steroids may increase mortality, likely because the underlying pathology is often diffuse alveolar damage rather than steroid-responsive inflammation. One therapy that should not be used is cyclophosphamide combined with steroids, which has been shown to increase mortality in acute exacerbations of IPF. Respiratory support becomes the next critical decision point. Many patients develop severe hypoxemic respiratory failure, but outcomes with invasive mechanical ventilation are poor. Across multiple studies: • In-hospital mortality ranges from 66–79% in ventilated ILD patients • Only ~20% of ventilated IPF patients survive to hospital discharge Ventilator management therefore focuses on lung-protective strategies, similar to ARDS care: • Low tidal volumes • Plateau pressures ≤30 cm H₂O • Avoid excessive PEEP, which has been associated with worse outcomes • Careful fluid management to prevent worsening pulmonary edema Because survival after intubation is so limited, early discussions about goals of care are essential. Noninvasive ventilation or high-flow nasal oxygen may be appropriate for selected patients who decline intubation. Prevention is therefore critically important. Antifibrotic therapies have significantly reduced exacerbation risk in IPF. Two major agents are used: • Nintedanib – shown in the INPULSIS trials to reduce the risk of acute exacerbations • Pirfenidone – also associated with lower exacerbation rates in multiple studies Meta-analyses show antifibrotics reduce the risk of acute exacerbations by roughly 37%, and nintedanib has also been approved for progressive fibrosing ILDs beyond IPF, after the INBUILD trial demonstrated substantial slowing of lung function decline. New therapies are also emerging. The FIBRONEER-ILD trial studied nerandomilast, a novel PDE-4 inhibitor, and although the composite endpoint did not reach statistical significance, the study demonstrated a meaningful reduction in mortality, suggesting a potential future role in progressive pulmonary fibrosis. Another key strategy is early referral for lung transplantation, particularly in patients with progressive fibrotic disease. Acute exacerbations can occur unpredictably and often represent a terminal event in advanced ILD, making transplant evaluation crucial before severe deterioration occurs. We close with the key system moves for inpatient teams: • Recognize sudden respiratory decline in patients with fibrotic lung disease • Confirm new bilateral ground-glass opacities on CT • Aggressively rule out infection, pulmonary embolism, and heart failure • Consider corticosteroids, particularly in non-IPF ILD • Use lung-protective ventilation if respiratory failure develops • Discuss prognosis early and involve palliative care • Ensure patients with fibrotic ILD are on antifibrotic therapy when appropriate Acute exacerbation of ILD remains one of the most devastating events in pulmonary medicine—but early recognition, careful ...
    Show More Show Less
    45 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.